Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...
The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...
Medpage Today on MSN11dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...
Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback